Details of the Drug | DrugMAP

General Information of Drug (ID: DMACVU8)

Drug Name

Aglatimagene besadenovec

Indication

Disease Entry	ICD 11	Status	REF
Hepatocellular carcinoma	2C12.02	Phase 3	[1]
Prostate cancer	2C82.0	Phase 3	[2]
Malignant glioma	2A00.0	Phase 2	[3]
Pediatric glioma	2A00.0	Phase 2	[2]
Pancreatic cancer	2C10	Phase 1/2	[2]
Malignant pleural effusion	2D72	Phase 1	[2]
------------------------------------------------------------------------------------


⏷ Show the Full List of Indication(s)

Drug Type

Gene therapy

Cross-matching ID

TTD ID: DE8H1W

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

References

1	ClinicalTrials.gov (NCT03313596) Multicenter RCT of ADV-TK Gene Therapy Improving the Outcome of Liver Transplantation for Advanced HCC. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	ClinicalTrials.gov (NCT00589875) Phase 2a Study of AdV-tk With Standard Radiation Therapy for Malignant Glioma (BrTK02). U.S. National Institutes of Health.